Opinion|Videos|August 12, 2024
Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib
An oncology specialist outlines their general approach to managing treatment-related atrial fibrillation in patients receiving BTK inhibitor therapy, incorporating insights from recent clinical data to inform their management strategies.
Advertisement
Episodes in this series
- Dr Parrondo:What is your general approach in managing treatment-related Afib in patients receiving treatment with BTKi inhibitors? What insights do recent data provide?
- Kaiser RWD -
Krackeler, et al. ASCO 2024. Abs 11158 @54:33 zanubrutinib go away over time. Less cardiac
- Kaiser RWD -
- What is the role of medications for anticoagulation and rhythm control? Dose reductions/holds?When do you involve cardiology?
- When may alternative therapy be warranted and what is your approach in these scenarios?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
The OncFive: Top Oncology Articles for the Week of 8/30
5